[The effect of beta-blocking agents on lipids metabolism].
Koyama
Y
Y
Division of Atherosclerosis, Metabolism, and Clinical Nutrition, National Cardiovascular Center.
Harano
Y
Y
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D006973:Hypertension / Q000188:drug therapy; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D050356:Lipid Metabolism; D008071:Lipoprotein Lipase / Q000037:antagonists & inhibitors; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000037:antagonists & inhibitors; D014664:Vasodilation / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D007328:Insulin; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D008071:Lipoprotein Lipase